Spondyloarthritis & psoriatic arthritis
Vision-related quality of life in spondyloarthritis patients with acute anterior uveitis on golimumab: the GO-VISION study
Authors' conclusion
GO-VISION suggests the effectiveness of GOL in preventing SpA-AAU flares, improving HRQoL, and enhancing productivity, highlighting the importance of patient-reported outcomes.
Study context
- Population
- Spondyloarthritis (SpA) patients with recent SpA-associated acute anterior uveitis (55% male, 75% tumour necrosis factor-inhibitors (TNFi)-naive, mean age 45.2)
- Participants
- 20 patients
- Exposure
- Golimumab: 2 years before vs 48 weeks after initiation; baseline vs 24 and 48 weeks
- GOLn = 20
- Outcome
- Effects of GOL on vision-related QoL and health-related quality of life (HRQoL), and health-related work productivity
- Follow-up
- 48 weeks
Methodological detailsmulticentre, single-arm, before–after comparison
- Multicentre
- Single-arm
- Before–after comparison
Main finding
As reported in the abstract
- Acute anterior uveitis (AAU) flares, 2 years pre-GOL to during treatment
- 50 to 2
- AAU incidence rate per 100 patient-years, pre-GOL to during treatment (p<0.01)
- 1.82 to 0.10
- NEI VFQ-25 total score (all p<0.02)
- 71.85-90.10
- EQ index (all p<0.02)
- 0.74-0.89
- SF-36 physical/mental scores (all p<0.02)
- 39.89/49.95 to 60.09/65.86
- Hours lost to uveitis (all p<0.02)
- 4 to 0
Observational data: associations, not effects.
Safety
| Outcome | Values |
|---|---|
| Mild TNFi-related adverse events | GOL 2 events |
Original publication
Vision-related quality of life in spondyloarthritis patients with acute anterior uveitis on golimumab: the GO-VISION study. Clin Exp Rheumatol. Published 21 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →